Skip to main content
رجوع
Watch Compare

ANAVEX LIFE SCIENCES CORP.

جودة البيانات: 83%
AVXL
NASDAQ Manufacturing Chemicals
KWD 3.12
▲ KWD 0.01 (0.32%)
6 months return
—
Momentum
Neutral
ROE
-36.72%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-36.72%
أعلى من متوسط القطاع (-54.49%)
ROIC-29.93%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current RatioN/A
Interest Coverage-10.22

التقييم

PE (TTM|NTM)
-7.06 | -21.07
أقل من متوسط القطاع (-1.50)
P/B Ratio2.23
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -34.08 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

2 محللين
Buy
+605.1%
upside to target
الحالي
KWD 3.12
Consensus Target
KWD 22.00
KWD 20.00
أدنى
KWD 24.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-21.07
ربحية السهم المستقبلية
-KWD 0.14
الإيرادات المقدّرة
36.50 M

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.08 · Rev Est: 0.0
Q12025 Q22025 2026-Q1 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 0.13 -KWD 0.16 -KWD 0.06 -KWD 0.11 -KWD 0.06 — —
Estimate -KWD 0.15 -KWD 0.15 -KWD 0.08 -KWD 0.15 -KWD 0.11 -KWD 0.08 -KWD 0.08
المفاجأة +13.33% -10.34% +20.00% +26.67% +45.45% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -36.72% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -39.95 M
ROE -36.72% ROA -33.94%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -34.08 M
ROIC -29.93% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: N/A
Debt / Equity N/A Current Ratio N/A
Interest Coverage -10.22 Asset Turnover N/A
Working Capital N/A Tangible Book Value 126.62 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -7.06 · EV/EBITDA: N/A
P/E Ratio -7.06 Forward P/E -21.07
P/B Ratio 2.23 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 7.73 Fwd Earnings Yield N/A
FCF Yield -12.08%
Market Cap 282.19 M Enterprise Value 150.44 M

Per Share

EPS: -0.46 · FCF/Share: -0.37
EPS (Diluted TTM) -0.46 Revenue / Share N/A
FCF / Share -0.37 OCF / Share -0.37
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 85.30% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 85.30%
SBC-Adj. FCF -43.01 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -46.38 M -43.00 M -47.51 M -47.98 M -37.91 M
EPS (Diluted) -0.54 -0.52 -0.60 — —
Gross Profit — — — — —
Operating Income -51.41 M -52.88 M -55.76 M -50.99 M —
EBITDA — — — — —
R&D Expenses 37.59 M 41.84 M 43.72 M 37.92 M 32.98 M
SG&A Expenses 13.82 M — — — —
D&A — — — — —
Interest Expense 4.68 M 7.32 M 6.52 M 946,988.0 26,261.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 103.82 M 135.57 M 154.39 M 152.70 M 161.62 M
Total Liabilities 8.95 M 15.30 M 12.53 M 10.21 M 10.80 M
Shareholders' Equity 94.87 M 120.26 M 141.85 M 142.49 M 150.82 M
Total Debt — — — — —
Cash & Equivalents 102.58 M 132.19 M 151.02 M 149.16 M 152.11 M
Current Assets — — — — —
Current Liabilities — — — — —

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -7.1 -1.5
P/B 2.2 1.6
ROE % -36.7 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock
LABU logo LABU Direxion Daily S&P Biotech Bull 3X ETF
0.18% weight
IRSSX IRSSX
0.03% weight
ISCB logo ISCB iShares Morningstar Small-Cap ETF
0.02% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0.02% weight
IIRSX IIRSX
0.01% weight
IRCIX IRCIX
0.01% weight
IRSIX IRSIX
0.01% weight
VVICX VVICX
0.01% weight
WINDX WINDX
0.00% weight
WFIVX WFIVX
0.00% weight